Flo Health, creator of the popular Flo app, and biopharmaceutical company Myovant Sciences are partnering together to create a digital tool that screens women for heavy menstrual bleeding.
The companies announced their deal on Monday, Oct. 8, with the goal of addressing the condition that affects about 25 percent of women and is associated with uterine fibroids. The digital tool will be embedded into the Flo app and help women keep track of their menstrual bleeding, identify any concerns and connect them to a healthcare professional.
"We are pleased to enter into this first-of-its-kind partnership, combining Myovant's clinical development expertise with Flo's innovative technology,” Lynn Seely, MD, Myovant Sciences president and chief executive officer, said in a statement. “Our aim is for this initiative to result in important insights and data that will empower women to take a more proactive role in their personal health.”
The Flo app is a platform that uses data science and artificial intelligence (AI) to help women track their ovulation and period cycle. By using AI, the app provides personalized content to specific users. According to its website, it has 22 million monthly users and 5 million daily users.
Myovant Sciences is a clinical-stage biotechnology company that focuses on developing and commercializing innovative therapies for women’s health and endocrine diseases.
"We share Myovant's mission of empowering women to take charge of their health, including in the area of tracking and better understanding heavy menstrual bleeding," Flo Health President Yuri Gurski said in a statement. "By partnering with Myovant to create improved digital tools for evaluating and researching periods, we are moving closer to achieving this mission."